The “age of genomic health/medicine screening” is being introduced into prenatal care through the prenatal genetic screening programs. The discussion and rigor that is expected by the industry and the provider for this genomic screening—in both the pre- and post-test arenas—for a patient-informed consent process is extensive.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Obstetrics and Gynaecology Canada
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Screening for Disease.(Available at:)Accessed on March 30, 2017)
- Alberta Prenatal Record Part 1 and 2 [Internet].(Available at:)Accessed on March 30, 2017)
- Stakeholder attitudes and needs regarding cell-free DNA testing.Curr Opin Obstet Gynecol. 2016; 28: 125-131
Published online: August 17, 2017
Accepted: May 10, 2017
Received: March 31, 2017
Competing interests: None declared.
© 2017 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- CorrectionJournal of Obstetrics and Gynaecology Canada Vol. 40Issue 9